STRATTERA 18mg price in UAE

Overview

Welcome to Dwaey, specifically on STRATTERA 18mg Capsules (Hard Gelatin) page.
This medicine contains an important and useful components, as it consists of Atomoxetine HCl.
STRATTERA 18mg is available in the market in concentration 18mg/Capsule and in the form of Capsules (Hard Gelatin).

LILLY SA is the producer of STRATTERA 18mg and it is imported from SPAIN, The most popular alternatives of STRATTERA 18mg are listed downward .

Mode Of Action

Atomoxetine hydrochloride selectively inhibits noradrenaline reuptake w/ minimal affinity for other noradrenergic receptors or for other neurotransmitter receptors or transporters. It is used in the treatment of attention deficit hyperactivity disorder.

Indication

Attention deficit hyperactivity disorder (ADHD)

Precaution

Monitor height and wt gain especially during the initial period of treatment; dose reduction or treatment interruption may be needed in children whose growth or wt gain is not satisfactory. Patients with high BP or cardiovascular conditions that may be worsened by increases in BP or heart rate. Caution when used in patients with a history of psychotic illness or bipolar disorder. May increase the risk of urinary obstruction or hesitancy. Monitor for signs of clinical worsening, suicidality or unusual behavioural changes especially during the start of treatment and during dose changes. Safety and efficacy have not been established in patients <6 yr. Not recommended for use in pregnancy. Lactation: Unknown whether drug is excreted in milk; use with caution

Side Effects

>10% Xerostomia (dry mouth) (21%)
Headache (2-19%)
Abdominal pain (7-18%)
Decreased appetite (11-16%)
Insomnia (2-15%)
Cough (11%)
Somnolence (11%)
Vomiting (3-11%) 1-10% Nausea (10%)
Increases in blood pressure (BP; ?15-20 mm Hg) and heart rate (HR; ?20 beats/min) (5-10%)
Erectile dysfunction (9%)
Hot flashes (8%)
Dizziness (5-8%)
Urinary hesitation or retention (7%)
Decreased weight (4-7%)
Depression (4-7%)
Irritability (<6%)
Dyspepsia (4%)
Ejaculation disorder (3%)
Sinus headache (3%)
Constipation (2%)
Dermatitis (2%)
Menstrual disorder (2%)
Mood swings (1-2%)

Contra indication

Angle-closure glaucoma. Not to be used with or within 14 days of discontinuing treatment with MAOIs.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May cause additive effect when used w/ drugs that increase BP. May potentiate the effect of salbutamol on the CVS. May increase risk of cardiac events when used w/ drugs that affect cardiac conduction or electrolyte balance, or that inhibit CYP2D6 (e.g. fluoxetine, paroxetine, quinidine). Increased risk of QT prolongation w/ QT prolonging drugs (e.g. class Ia and III antiarrhythmics, moxifloxacin, erythromycin, TCAs, lithium, cisapride). Increased risk of seizures w/ drugs that are known to lower seizure threshold (e.g. phenothiazines, neuroleptics, mefloquine, bupropion, tramadol). Potentially Fatal: Increased neurotoxic effect w/ MAOIs.